MedTrace Logo

A Study To Investigate The Safety And Efficacy Of CP- 690,550 In Patients With Moderate And Severe Ulcerative Colitis.

NCT00787202 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 195

Last updated 2013-04-16

Study results available
· View outcomes & findings →

Summary

The hypothesis of the study is that at least one dose of CP 690 550 is superior to placebo (inactive drug) in inducing remission in patients with moderate to severe ulcerative colitis.

Conditions

Interventions

DRUG

CP- 690 550

Administration via oral route twice daily for the duration of treatment

DRUG

CP- 690 550

Administration via oral route twice daily for the duration of treatment

DRUG

CP- 690 550

Administration via oral route twice daily for the duration of treatment

DRUG

CP- 690 550

Administration via oral route twice daily for the duration of treatment

OTHER

placebo

Administration via oral route twice daily for the duration of treatment

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-12-31
Primary Completion
2010-09-30
Completion
2010-09-30

Countries

  • Belgium
  • Brazil
  • Chile
  • Czechia
  • Denmark
  • France
  • Hungary
  • Israel
  • Italy
  • Mexico
  • Netherlands
  • Poland
  • Slovakia
  • South Africa
  • Spain
  • Sweden
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00787202 on ClinicalTrials.gov